Focused on emerging fields of synthetic lethality, innate immunity, and RNA modulation

858 Therapeutics is a clinical-stage drug discovery and biotechnology company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology and immunology.

858 was founded by a veteran management team that brings a long track record of success in pharma and biotech research and development. 858 scientists are dedicated to the company's mission to discover innovative and meaningful drugs for patients with cancer and immune diseases. Its lead program is a PARG inhibitor in early clinical development.

858 is headquartered in the biotech hub of San Diego, CA.